Literature DB >> 22246243

Can a gastrointestinal pathologist identify microsatellite instability in colorectal cancer with reproducibility and a high degree of specificity?

Eli Brazowski1, Paul Rozen, Sara Pel, Ziona Samuel, Irit Solar, Guy Rosner.   

Abstract

Clinical features usually initiate evaluation for Lynch Syndrome (LS) but some colorectal cancer (CRC) histopathology findings are compatible with high microsatellite instability (MSI-H) that also occurs in LS. This led to the suggestion that pathologists request MSI analysis, which is an expensive addition to routine histology. We aimed to see if a Gastrointestinal Pathologist could identify MSI-H features with reproducibility and high (95%) specificity (MSI-H 95%). Histopathology of all CRCs received during 2005 and 4 MSI-H controls were scored using 2 published methods, "MsScore" and "PathScore". MSI analysis was performed on CRCs scored by either method as probable MSI-H 95% and results compared. To examine reproducibility of histopathology, 100 coded slides, including 25 scored MSI-H 95% and 75 scored low, were re-examined to now identify those needing MSI analysis. Costs were evaluated for identifying MSI-H with or without scoring. All 227 CRCs were scored for possible MSI-H 95%; 24 had high scores and MSI analysis. DNA analysis proved 14 MSI-H, PathScore identified 13 (95%), MsPath identified 9 (64%), histopathology alone identified 7 (50%). Reproducibility for identifying histopathology characteristics of MSI-H at re-examination, without scoring, was "moderate agreement" (Kappa statistic = 0.4615). Costs for identifying MSI-H by PathScore were the lowest, $436/identification. Conclusions; PathScore identified the most proven MSI-H CRCs at lowest cost and even an experienced gastrointestinal pathologist has difficulties identify MSI-H without scoring. So, scoring can be facilitated by a computerized evaluation form for routine CRC histology, prompting score computation and recommendation for MSI analysis with high specificity.

Entities:  

Mesh:

Year:  2012        PMID: 22246243     DOI: 10.1007/s10689-012-9508-8

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  23 in total

1.  Young age and a positive family history of colorectal cancer are complementary selection criteria for the identification of Lynch syndrome.

Authors:  P Manders; L Spruijt; C M Kets; H W Willems; D Bodmer; K M Hebeda; I D Nagtegaal; J H J M van Krieken; M J L Ligtenberg; N Hoogerbrugge
Journal:  Eur J Cancer       Date:  2011-01-25       Impact factor: 9.162

2.  How helpful is age at colorectal cancer onset in finding hereditary nonpolyposis colorectal cancer?

Authors:  Patrick M Lynch
Journal:  Clin Gastroenterol Hepatol       Date:  2011-04-11       Impact factor: 11.382

3.  Comparison between universal molecular screening for Lynch syndrome and revised Bethesda guidelines in a large population-based cohort of patients with colorectal cancer.

Authors:  Lucía Pérez-Carbonell; Clara Ruiz-Ponte; Carla Guarinos; Cristina Alenda; Artemio Payá; Alejandro Brea; Cecilia M Egoavil; Adela Castillejo; Victor M Barberá; Xavier Bessa; Rosa M Xicola; María Rodríguez-Soler; Cristina Sánchez-Fortún; Nuria Acame; Sergi Castellví-Bel; Virgínia Piñol; Francesc Balaguer; Luis Bujanda; María-Luisa De-Castro; Xavier Llor; Montserrat Andreu; Angel Carracedo; José-Luis Soto; Antoni Castells; Rodrigo Jover
Journal:  Gut       Date:  2011-08-25       Impact factor: 23.059

4.  Microsatellite instability of the colorectal carcinoma can be predicted in the conventional pathologic examination. A prospective multicentric study and the statistical analysis of 615 cases consolidate our previously proposed logistic regression model.

Authors:  Ruth Román; Montse Verdú; Miquel Calvo; August Vidal; Xavier Sanjuan; Mireya Jimeno; Antonio Salas; Josefina Autonell; Isabel Trias; Marta González; Beatriz García; Natalia Rodón; Xavier Puig
Journal:  Virchows Arch       Date:  2010-05       Impact factor: 4.064

Review 5.  Pathology of hereditary nonpolyposis colorectal cancer.

Authors:  J R Jass
Journal:  Ann N Y Acad Sci       Date:  2000-06       Impact factor: 5.691

6.  Immunohistochemistry to detect hereditary nonpolyposis colorectal cancer in young patients: the 7-year Auckland experience.

Authors:  Deborah M Wright; Julie L Arnold; Bryan Parry; Michael Hulme-Moir; Ingrid M Winship; Susan Parry
Journal:  Dis Colon Rectum       Date:  2011-05       Impact factor: 4.585

7.  Population-based detection of Lynch syndrome in young colorectal cancer patients using microsatellite instability as the initial test.

Authors:  Lyn Schofield; Natasha Watson; Fabienne Grieu; Wei Qi Li; Nik Zeps; Jennet Harvey; Colin Stewart; Michael Abdo; Jack Goldblatt; Barry Iacopetta
Journal:  Int J Cancer       Date:  2009-03-01       Impact factor: 7.396

8.  Value of histopathology in predicting microsatellite instability in hereditary nonpolyposis colorectal cancer and sporadic colorectal cancer.

Authors:  Jinru Shia; Nathan A Ellis; Philip B Paty; Garrett M Nash; Jing Qin; Kenneth Offit; Xin-Min Zhang; Arnold J Markowitz; Khedoudja Nafa; Jose G Guillem; W Douglas Wong; William L Gerald; David S Klimstra
Journal:  Am J Surg Pathol       Date:  2003-11       Impact factor: 6.394

9.  Identifying Lynch syndrome: we are all responsible.

Authors:  Julian A Sanchez; Jon D Vogel; Matthew F Kalady; Mary P Bronner; Marek Skacel; James M Church
Journal:  Dis Colon Rectum       Date:  2008-08-06       Impact factor: 4.585

10.  Pathology features in Bethesda guidelines predict colorectal cancer microsatellite instability: a population-based study.

Authors:  Mark A Jenkins; Shinichi Hayashi; Anne-Marie O'Shea; Lawrence J Burgart; Tom C Smyrk; David Shimizu; Paul M Waring; Andrew R Ruszkiewicz; Aaron F Pollett; Mark Redston; Melissa A Barker; John A Baron; Graham R Casey; James G Dowty; Graham G Giles; Paul Limburg; Polly Newcomb; Joanne P Young; Michael D Walsh; Stephen N Thibodeau; Noralane M Lindor; Loïc Lemarchand; Steven Gallinger; Robert W Haile; John D Potter; John L Hopper; Jeremy R Jass
Journal:  Gastroenterology       Date:  2007-04-25       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.